{'fraction_non_alphanumeric': 0.02198852772466539, 'fraction_numerical': 0.009560229445506692, 'mean_word_length': 5.307228915662651, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
What the neighbors say

Cancer is an established cause of venous thrombosis, and hematologic malignancies lead to high risks. Generally, the association between cancer and thrombosis is the result of hospitalization, immobilization, treatment and cancer-specific factors, while particularly the mechanism of the latter is not fully elucidated. Thrombosis is a poor prognostic sign in cancer. Kekre and colleagues (Haematologica) investigated thrombosis incidence in over 2000 recipients of allogeneic stem cell transplantation. They found a cumulative incidence of venous thrombosis of 5.5% at 1 year and 7.1% at 2 years. Patients who developed either acute or chronic graft versus host disease had an approximately two-fold higher risk of venous thrombosis than those who did not. The study design did not allow analyses into the mechanism of the thrombosis, which could be related to endothelial damage or other treatment consequences, or to hospitalization and immobilization. The study confirmed venous thrombosis as a predictor of mortality.